Robeco Institutional Asset Management B.V. has recently increased its holdings in Insulet Corporation ($NASDAQ:PODD), in a move that is sure to have a positive effect on the company’s share price. Insulet Corporation is a medical technology company specializing in the development and commercialization of insulin delivery systems for people living with diabetes. They are a leader in the industry in developing innovative products such as the Omnipod, an insulin pump delivery device that eliminates the need for multiple daily injections. Insulet Corporation’s commitment to innovation and customer service has continued to drive their success over the years. Their products are designed to make life easier for those living with diabetes and they are constantly working to improve functionality and usability of their products.
In addition, they have developed partnerships with other leading companies in the medical technology space to expand their product offerings and help even more people manage their diabetes effectively. With their commitment to innovation and customer service, they are sure to continue to be a leader in the medical technology space for many years to come.
On Monday, Robeco Institutional Asset Management B.V. made a significant investment in Insulet Corporation. The stock opened at $263.1 and closed at $260.8, down by 0.9% from the previous closing price of 263.1. This marks a significant increase from Robeco Institutional Asset Management B.V.’s previous investment in Insulet Corporation, suggesting the company’s stock is on the rise despite Monday’s slight dip in price. Insulet Corporation is a leader in developing and manufacturing products that enhance the lives of patients with diabetes and other chronic conditions, and Robeco Institutional Asset Management B.V.’s decision to increase their investment in the company is a testament to their confidence in Insulet Corporation’s ability to continue providing these quality products. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Insulet Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Insulet Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Insulet Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Insulet Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Insulet Corporation Stock Intrinsic Value
At GoodWhale, we have been analyzing INSULET CORPORATION‘s fundamentals and have come to the conclusion that the fair value of INSULET CORPORATION share is around $318.6, calculated by our proprietary Valuation Line. This offers an opportunity for investors to capitalize on the discrepancy between the fair value and the current market price. More…
Risk Rating Analysis
Star Chart Analysis
Insulet Corp is a company that manufactures and sells insulin pumps. Its main competitors are Antibe Therapeutics Inc, NuGen Medical Devices Inc, and NanoVibronix Inc. All of these companies offer similar products and services. Insulet Corp has a competitive advantage because it has a more established brand name and a larger customer base.
– Antibe Therapeutics Inc ($TSX:ATE)
Antiobiotics are a class of drugs that are used to treat infections by bacteria. Antibe Therapeutics Inc is a Canadian company that is focused on the development of safer and more effective antibiotics. The company has a market cap of 29.71M as of 2022 and a Return on Equity of -28.09%.
– NuGen Medical Devices Inc ($TSXV:NGMD)
NuGen Medical Devices Inc is a publicly traded company with a market capitalization of 6.58M as of 2022. The company has a negative return on equity of -11235.95%. NuGen Medical Devices Inc is engaged in the development, manufacture and commercialization of medical devices. The company’s products include catheters, implants, and other medical devices.
NanoVibronix Inc is a medical device company that develops and commercializes proprietary therapeutic ultrasound products. The company’s products are based on its patented NanoVibronix Platform, a unique, low-intensity, surface-based ultrasound technology. NanoVibronix’s products are used in a variety of medical applications, including wound care, urology, physical therapy, cosmetic surgery, and pain management.
NanoVibronix’s market cap is $12.04 million as of 2022. The company has a return on equity of -190.59%. NanoVibronix’s products are based on its patented NanoVibronix Platform, a unique, low-intensity, surface-based ultrasound technology. NanoVibronix’s products are used in a variety of medical applications, including wound care, urology, physical therapy, cosmetic surgery, and pain management.
Robeco Institutional Asset Management B.V. recently increased its holdings in Insulet Corporation (NASDAQ: PODD), a medical device company that develops, manufactures, and sells insulin delivery systems for people with diabetes. The firm’s analysis suggests that the company has strong fundamentals and a promising outlook, making it an attractive investment opportunity. Insulet’s primary product, the Omnipod insulin management system, has seen rapid growth in recent years due to its reliable and user-friendly design. Furthermore, the company has strengthened its partnerships with industry leaders such as Eli Lilly and Walmart to improve access to its products.
In addition, Insulet recently acquired Diabeloop, a diabetes management platform, which is expected to benefit the company’s growth. Analysts are bullish about Insulet’s future prospects and view it as a good long-term investment.